A study by Castiglioni et al. [43] found that inhibiting transforming growth factor-beta (TGF-β) signaling in conjunction with PD-1 blockade significantly enhanced T cell-mediated tumor rejection in a colorectal cancer murine model. This evidence concerns the gene TGFB1 and neoplasm.